Medical Necessity and Appropriateness of Xeomin for Pectoralis Minor Syndrome

Evidence Against Medical Necessity

The American Society of Anesthesiologists recommends that botulinum toxin should not be used in the routine care of patients with myofascial pain, based on randomized controlled trials showing equivocal findings when comparing botulinum toxin type A with saline placebo for myofascial pain 1, 2.
The American Society of Anesthesiologists found that the only musculoskeletal indication where botulinum toxin showed Category A2 evidence was piriformis syndrome, which is not applicable to this patient's diagnosis 1, 2.
The American Heart Association/American Stroke Association guidelines support botulinum toxin injection to reduce severe hypertonicity in hemiplegic shoulder muscles, but this recommendation applies specifically to post-stroke spasticity with upper motor neuron syndrome, which is not this patient's condition 4, 5, 6.

The American Heart Association/American Stroke Association guidelines suggest that optimizing physical therapy adherence is crucial, as the patient reports inconsistent attendance due to scheduling conflicts, which undermines the primary evidence-based treatment 4, 7.
The American Stroke Association recommends trialing neuromodulating medications like gabapentin, pregabalin, or duloxetine, which have stronger evidence (Class IIa, Level A) for neuropathic pain components 4, 5, 8.
The American Heart Association/American Stroke Association guidelines suggest considering suprascapular nerve block, which has Level B evidence for shoulder pain with both nociceptive and neuropathic mechanisms, showing superiority to placebo for up to 12 weeks 4, 5, 6.

The Journal of the American Geriatrics Society recommends continued physical therapy with emphasis on gentle stretching and mobilization, analgesics, and neuromodulating medications for neuropathic pain components as the standard of care for post-mastectomy chest wall pain with myofascial components 7, 8, 10.
The American Geriatrics Society suggests that muscle relaxants like tizanidine, which the patient is already taking with benefit, should be continued 10.

The Anesthesiology journal notes that botulinum toxin does not meet standard of care criteria for this indication based on current medical evidence, and its use may be associated with potential risks, including local muscle weakness, dysphagia, and pregnancy exposure concerns 1, 2.